Arkema S.A. (AKE) Earnings Call Transcript
February 26, 2026
Earnings Call Speaker Segments
Good morning, everyone. Welcome to the conference call covering Arkema's results for the full year 2025. Joining me today are Marie-José, our CFO, and the Investor Relations team. The slides we're using during this webcast are, as usual, posted on our website, and Marie-José and I will both be on hand to take your questions once the presentation wraps up. Looking at 2025, the macroeconomic backdrop proved especially demanding — arguably among the toughest conditions our industry has confronted over the past 20 years. The latter half of the year was particularly notable for weak demand in numerous end markets, with the US slowing down while Europe stayed at low levels. This mirrored continued caution among economic players, along with strict inventory management at year-end across many of our customers. Conversely, Asia remained the group's most vibrant region, China especially, where we observed acceleration in some sectors such as electric mobility, advanced electronics, and sustainable consumer goods too. As you might imagine given this situation, the group concentrated on its fundamentals — proximity to customers and innovation — while reinforcing its cost and cash initiatives. Our teams have been fully engaged every day to best navigate the environment and keep operations under strict control.
So because of that, we produced a substantial amount of cash — €464 million — which was well above the revised guidance we had given of €300 million. That result also came in stronger than last year's figure, even with the considerable drop in EBITDA. EBITDA came in at €1.25 billion, a margin of 13.8% — close to 14% — which fell short of what we had expected when the year began, though it was in line with what the majority of our peers went through. We managed to counter fixed cost inflation and delivered roughly €90 million in fixed and variable cost savings during 2025, which is nearly double the initial annual target we set at CMD. That effort will carry on into 2026 as we work to offset inflation once again, and as a result we should be in a position to hit the 2028 cumulative cost savings target of €250 million two years ahead of schedule. As slide seven shows, the group has rolled out a number of new initiatives aimed at making the organization more efficient still, which brought headcount down by more than 2% in 2025, and we expect a further reduction of approximately 3% per year across the next three years. Several of our key attractive markets kept supporting our performance — specifically batteries, sports, 3D printing, healthcare, and new-generation fluorospecialties with low global warming potential — and these enjoyed strong momentum, with sales rising 16% year on year.
Going forward, these markets are set to keep expanding and will help drive the ramp-up of the key projects we've listed on slide five. Those projects contributed roughly €60 million of extra EBITDA in 2025, and we anticipate that momentum carrying into 2026. The group stands to gain from the ramp-up of our recent investments in the US and Asia, which got off to a successful start in 2025 and early 2026 — specifically our new 1233zd and DMDS unit in the US, along with the recently added clear transparent polyamide capacity situated downstream of the polyamide 11 plant in Singapore. On top of that, our PVDF investment in the US is scheduled to come on stream during the first half of 2026, lifting our capacity in that region by 50%. PIAM ought to keep gaining from the introduction of new smartphones — particularly foldable and ultra-thin models — where polyimide is increasingly indispensable for meeting their tougher reliability and thermal management demands. PIAM should likewise begin to reap the rewards of successful diversification into fresh high-end applications across industry markets. Following this substantial wave of organic projects, which offers considerable room for growth over the midterm, Arkema will trim its CapEx envelope further, down to €600 million in 2026. At that level, the group will be able to keep investing in targeted projects that deliver high returns and quick payback.
Our focus wasn't solely on the near term — we also kept building Arkema for the future, forming strategic partnerships with leaders in their fields to reinforce our position in key markets like batteries and sports. Staying differentiated and speeding up growth in high-end applications makes continued R&D investment essential. Sustainable innovation remains our focus. We draw on our expertise by working alongside startups. OUI? in carbon capture is a strong illustration. Turning back to 2025 EBITDA performance, apart from the currency headwind, the low cycle in upstream acrylics and the drop in old-generation refrigerant accounted for the bulk of the decline. The remaining Arkema businesses proved much more resilient, yet to some degree these other activities overshadowed that result. So, to make the group's results easier to read, we've chosen to put a new segmentation in place starting in 2026, the aim being to better spotlight the distinct dynamics and business models of the resilient, fast-growing platforms within Specialty Materials versus the more cyclical, large-scale industrial activities, which will be regrouped into a new segment called Primary Materials. This new segment will include the global acrylic monomer business.
As slide 21 shows, this business has been far more volatile lately than it previously was. That said, if you look back to when we acquired our American asset in 2010, this activity has generated a tremendous amount of cash, and it played a big part in funding the transformation of the group's portfolio in the years since. Thanks to our strong industrial and commercial position in acrylics, we will keep leveraging it to deliver solid cash generation and capital returns through the cycle. The new segmentation will also give more visibility to our next-generation low-GWP solution for air conditioning, which we actively managed to strengthen their prospects. These will now sit within the Fluorospecialties portfolio and will gain from faster growth in applications such as heat pumps and data centers. Conversely, old-generation refrigerants — a highly profitable, cash-generative business since 2020, probably exceeding what a disposal could bring in — will join the Primary Materials segment. Although this business will fade quickly in the years ahead, Arkema will instead benefit, within the Specialty Materials segment, from the continuing growth of the low-GWP solution, which generates substantial value. In my view, this new segmentation will give the financial community greater transparency on the business drivers of Arkema's portfolio and on Specialty Materials performance.
And lastly, I want to take a moment to highlight some of our CSR achievements, where we again delivered strong progress and quite good performance in 2025. That's true for our climate plan: the many initiatives across the group aimed at cutting our carbon footprint are delivering results. By the end of 2025, we had lowered Scope 1 and 2 emissions by 48.7% versus 2019 — fully consistent with our target — and we've also chosen to raise our ambition on water withdrawals and set a new goal for waste treatment, which is another key priority for Arkema. Finally, in light of the strength of the group's balance sheet, the board has opted to put forward a stable dividend of €3.60 per share at the Annual General Meeting, despite the challenging macro environment — a signal of confidence both in the quality of the portfolio and in how relevant the strategy is. Thank you for your attention. I'll now turn things over to Marie-José, who will walk through the financial results in more detail before I return to talk about the outlook with you.
Thanks, Thierry, and good morning, everyone. As Thierry mentioned, 2025 proved to be a difficult year, beginning with revenues of €9.1 billion. Sales declined 5% compared with the prior year. A negative 2.9% currency effect weighed on us, driven mainly by the US dollar weakening against the euro, and also by other currencies such as the Chinese yuan and Korean won. The scope effect of plus 1.6% came from integrating Dow's laminating adhesives. Volumes fell 1.6%, a reflection of the broadly weak demand backdrop in Europe and North America, along with tight inventory management on the part of customers during the fourth quarter. Conversely, we kept benefiting from positive momentum in Asia, and especially in China, driven largely by High Performance Polymers. The price effect was negative 2.1%, due essentially to the acrylics cycle and to the refrigerant gases moving from old to new generation. Our other activities posted a smaller price decline of 0.9% amid falling raw material costs. Group EBITDA reached €1.25 billion, which includes a €40 million negative currency effect. Let me start with Q4, a quarter that is seasonally low. The drop in EBITDA during the fourth quarter reflected the broadly weak demand backdrop in Europe and the US, plus heavy destocking caused by tight year-end inventory management at our customers and, in fact, at ourselves, which weighed particularly on our Adhesives and Advanced Materials segments.
Turning to how each segment performed across the full year, the Adhesives margin landed at roughly 14% once you strip out the dilution from Dow's laminating adhesives business, which is still being integrated. For the full year, EBITDA bore the mark of soft demand in industrial adhesives and the second-half slowdown in the US, especially in flexible packaging, transportation, and construction. At Bostik, results kept drawing support from our continuous efficiency efforts and our pricing discipline. Advanced Materials held up well, with volumes and prices broadly stable, and posted an EBITDA margin of 17.9%. High Performance Polymers stood out in particular, delivering 2% organic growth for the year, helped by new business wins in batteries, sports, and 3D printing, along with the sustained positive momentum in Asia. Even so, the segment's EBITDA felt the hit from negative currency effects, an unfavorable mix in Performance Additives, and softer volumes in Europe and in US. In Coating, EBITDA suffered from low-cycle conditions in upstream acrylics and from the weak demand backdrop in coating markets. Construction and decorative paints markets in Europe and US were subdued. As a result, the segment's performance came in significantly below last year, even with downstream activities proving resilient.
And finally, Intermediates EBITDA was mainly affected by the refrigerants downturn during the first half, while acrylics in Asia saw a modest improvement. Group recurring EBIT came in at €564 million, equivalent to a 6.2% recurring EBIT margin. That figure accounts for €687 million in recurring fixed asset depreciation, which is above last year's level owing to the integration of Dow's laminating adhesives as well as the start of amortization for new production units that came online during 2025. Non-recurring items totaled €276 million. These comprise €144 million of PPA depreciation and €132 million of one-off charges, in particular the restructuring costs tied to the hydrogen peroxide site in France. Financial expenses were minus €125 million. The rise compared with last year mirrors higher interest costs on our bonds, on one hand, and lower interest earned on invested cash, on the other. Taking everything together, adjusted net income reached €328 million, equal to €4.34 per share. Turning to cash and debt, Arkema posted strong cash flow generation, with recurring cash flow at €464 million. That mirrors our ongoing efforts to keep working capital under tight control. The working capital ratio on annualized sales came to 12.5% on EBITDA, and the EBITDA to operating cash conversion rate was 88%.
Capital expenditure for us came to €636 million, which is under the recurring depreciation level in the P&L. Free cash flow reached €390 million, and that figure includes a non-recurring outflow of €74 million tied mainly to restructuring costs. With those elements factored in, Arkema's net debt plus hybrid bonds edged slightly lower to €3.2 billion, and within that total there is €1.1 billion of hybrid bonds. A strong balance sheet remains in place for the group, with a net debt to last 12 months EBITDA ratio of 2.5 times. Keep in mind that all our 2026 maturities were pre-financed during 2025. The €300 million outstanding hybrid bond that was issued in January 2020 got redeemed in January 2026, so at the end of this month, end of Jan, our hybrid bond portfolio is back at €800 million. I'll now hand it back over to Thierry.
Thank you, Marie-José, for walking us through that. We're now going to discuss how we see this year shaping up. As we entered the year, conditions remain — no real surprise there — essentially a carryover from the second half of last year, with visibility still limited and demand still soft. As you've observed, currency effects keep working against us, after the USD and Asian currencies weakened further relative to the euro. Against that backdrop, as we've already mentioned, our top priority will stay where it has been, and I believe we performed well on this front last year and will do so again this year, namely on the things we can control. That covers, specifically, fixed cost optimization, variable cost optimization, CapEx, and working capital. On top of that, we'll keep leaning on the gradual ramp-up of our major projects. It's coming along more slowly than we'd hoped, given the macro picture, but it remains significant for the company and will underpin Arkema's growth over the long term. For '26 versus '25, we expect roughly €50 million in additional EBITDA from this project. It will keep helping us this year and next to strengthen our geographic footprint, since we see greater long-term development potential in Asia and in the US.
With all of that in mind, for 2026 the group is targeting EBITDA growth that is slight on a constant-FX basis, and obviously we prefer to look at constant FX, because exchange rates have been unusually volatile against the euro — not just the USD, as I said, but the majority of Asian currencies too. The year-on-year comparison is going to be tougher in H1, and especially in Q1, because last year's profile was weighted more toward the first semester, with substantial destocking in the second half. On top of that, the currency effect in Q1 ought to be negative, which we estimate at €25 million. Setting the currency effect to one side, we expect the macro in 2026 to be more or less comparable to '25. The comparison with last year should gradually get easier as we move toward the end of the year, including in particular for Arkema the ramp-up of our major project. So as a result, we anticipate that the performance of the two halves will be more balanced in '26 than in '25. Thank you very much for your attention, and along with Marie-José, we are ready to take whatever questions you may have.
Thank you. Should you want to pose a question by phone, kindly hit star one on your keypad. Should you want to take your question back, kindly hit star two. Once more, kindly hit star one on your telephone so you can join the question queue, then wait until your name is called. Our first question is from Thomas Wrigglesworth at Morgan Stanley. Please proceed.
Thanks, Thierry, and thanks, Marie-José, for the chance to ask a couple of questions. First, could you speak a bit about construction end markets region by region and help us grasp how big a step-down you saw in the US during the second half and how much weight that carries into 2026? On the other side, expectations are that construction refreshment picks up in Europe in '26. Do you see anything in your order books or in your conversations with customers that speaks to that? Second, if I may, on the obviously very strong free cash flow in the fourth quarter: how much of that reflected your decision to really cut working capital versus the pricing element flowing through working capital? That is, as we look at working capital for '26, if we do start to see some volume improvement at some point, do you need a rapid increase in working capital to meet that demand? Thank you.
Marie-José will handle the working capital question. Regarding construction, that's an interesting one, since relative to other peers we carry more weight in construction, particularly in Europe and the US, while Asia accounts for less. I'd say — and this ties into your question — that to some degree the answer lies within your question itself. In Europe, we have certainly hit a bottom. I remain quite cautious about the signals, because surprises have caught us off guard several times. My sense is there's a slight incremental improvement, though it needs confirmation. Right? Europe is at the bottom, so to speak. It's no longer declining, and if a trend existed, it would be marginally better. In the US, the second semester was clearly one of the unpleasant surprises for us in terms of business development. I know how elastic and agile the US economy is, so I wouldn't necessarily extrapolate what we saw in the US during the second semester onto what this year might bring. What's clear — and this marks the difference from Europe — is that US construction declined in last year's second semester, whereas Europe appeared more to be at a bottom, with a somewhat more positive tilt.
As for the US, we’ll see. I’m aware that the Trump administration is working to implement certain steps aimed at supporting construction-related activities. We’ll see whether that provides some support, but there are so many variables that it’s hard to know today. I would be cautious, as I am on the overall macroeconomy. Let’s take it month by month and see how things develop.
Regarding cash, I’ll make a few points. Essentially, you observed that working capital came in at 12.5% of our annual sales, which frankly mirrors comparable efforts our customers have been making on their side. For 2026, assuming the macro backdrop stays constant, I would frankly anticipate working capital being flat. If a rebound occurs, then working capital should certainly rise proportionally relative to that 12.5% or 13% of our sales.
Thanks to you both. As a quick follow-up, would you say the industry or the supply chain has reduced inventories and working capital too far? It feels as though everyone cut hard at the close of last year and then cut hard once more in 20 at the end of 2025 — sorry, in '24 and '25. I suppose investors are taken aback by how extensive the destocking has been. Any remarks or insight you could offer on inventory levels across the system would be very useful.
Sure, that question is worth a great deal of money. The hard part — and you know as much about this as I do, Tom — lies in the chemicals supply chain. These chains are complicated, they stretch a long way, and they're fragmented, so getting a clear picture is always tough. What's certain is that, to some degree, this has been something of a puzzle for every one of us, since ordinarily a chemicals cycle doesn't run this long. It's evident that destocking is happening now. We were already discussing the end of destocking 18 months ago. We figured it had gone on long enough already. It's evident that inventories across most of the chain appear to be fairly low — but low only holds if a rebound shows up. If no rebound comes, the chain can certainly manage. My thinking remains unchanged. At some point, a rebound will arrive. We don't know when. It will happen. We don't know when. Once that rebound arrives, the chain will be under heavy strain. That much is obvious. We don't know when, and there will be variations depending on the region, the end market, the product line, and so on.
I mean, this is a normal chemical cycle where volume and price move in both directions depending on whether things go down or up, and that always amplifies what happens in the industry. So we need some patience, but it will arrive at some point. We'll see. Your question is a fair one. For sure, inventories are lower at the close of this year than they were at the close of '24. And '24 was lower than '23, the close of '23, but at this point demand is what will be the primary driver, not inventory.
I appreciate that.
Glad to have you with us.
Matthew Yates from Bank of America has our next question. You're up.
Morning, everyone, and thanks for the question. I want to ask about the new structure — the divisional restatement. This isn't the first time the company has done that since it was created. I heard your introductory remarks about the benefits of transparency, but I'd put it to you that some would argue it highlights a lack of industrial logic in the portfolio, given that you can move things around so frequently. It hurts investors' ability to track performance over time, because that transparency is lost. Could you elaborate a little more on why you think this is a good decision? And by association, have reporting lines or the management structure changed? I took a quick glance at your Exec Committee on the website, and it hasn't changed. Will there be a change in roles and responsibilities that may help us bring some better operational performance and some genuine benefit from this move? Thank you.
Matthew, we don't make changes all that frequently, and what we're discussing here is an incremental one. The challenge we ran into — and we're entirely willing to talk about this further with you and with anyone who'd like to — the challenge came down to two things. First, we had the sense that in the Specialty Material business, which by any definition makes up by far the biggest portion of Arkema's portfolio, we're genuinely performing very well, and this year we were frustrated because we couldn't read it clearly and neither could you, in a simple way. The cause was that circumstances shifted during the last three years. The world has moved on. Perhaps we've moved too, but I believe it's wise to stay agile and to aim for maximum transparency and clarity in a world undergoing a great deal of change, where you, we, and all our stakeholders are striving to grasp what's going on and what you can truly count on and build upon going forward. What we observed is that, in fact, with refrigerant gas, while we found that we were largely in old-generation gases with limited progress in new generation — which is exactly why we chose to sell it, since we saw no future there and it sat far from our sustainable strategy — what we observed is two things: the old generation, as we already knew, was being phased out or fading away, with that accelerating during the last two years, yet on the other hand, we are much stronger, much better, and much faster at developing new generation — not for the traditional refrigerant application, but for new applications: heat pump, data center, energy efficiency in the buildings, which are entirely core to Arkema's strategy, with some niches, same end market, same kind of growth pattern, etc.
We really wanted to acknowledge that, and that’s why one portion of this we separated into old and new generation, and from a portfolio perspective it makes total sense that this new generation—which we’ve already begun doing—joins the SPP. The second point, regarding acrylics, for a long period, and we had, I know, discussions together about this, we were fully convinced that for Europe and the US we would be capable of stabilizing their volatility by building out the downstream. That held true for Asia, but Asia we knew would be fairly limited, whereas Europe and the US, we believed we could go further along this path to balance upstream and downstream. In reality, we’ve found that the targets were not so numerous. In fact, we already acquired the majority of those targets with Sartomer and Coatex. The second thing was that not only did we decide, when we purchased Bostik, to direct most of our cash allocation for acquisitions toward adhesives. The second trend we’re seeing, which stems from the fact that the world is becoming much more volatile than it was in the old days—you can see it across every parameter, FX, also the macro figures in this or that market, etc., or the Brent evolution—in fact it strengthened the volatility of the acrylic acids, the acrylic monomers.
So we chose to combine China, Europe, and the US, and to acknowledge that within the portfolio there's a small minority — roughly 15% of it — that is inherently more volatile in nature, even if across the cycle it still produces a lot of cash. With acrylic, that's normal, since the upstream moves alongside the downstream, but upstream is a basic materials business. That much we know. Acrylic monomer is a basic material. We believe that with this shift in the world that we want to acknowledge — the greater volatility of what now sits in Primary Materials — we can genuinely demonstrate that all the work we've done on Specialty Materials is truly paying off, with considerable resilience and growth over time. It was against the backdrop of '25, a year that was entirely atypical and unexpected, that they managed to deliver a minus 5% EBITDA evolution, which, frankly, considering how challenging the context was, counted as quite a good performance. From our side, explaining it this way was much easier. You should take it as a clearer reading now. That's the reason we made the change.
We're ready to talk with any of you. For us, it reinforces how well the performance has been read, and also the benefit of the strategy we've been leading over the past 10 years.
Thierry, may I come back with a follow-up? From what you just said, it sounds as though the idea of integrating across the value chain has not succeeded and no longer holds up. That goes beyond merely how you are reporting it. It calls into question the company's actual strategy. Would you be open to the possibility of exiting the three upstream acrylic plants if a possible buyer were out there? Or do they remain core to the broader group?
No, I’d put it this way: we need to accept it for what it is, and that’s a stronger reading and report of where we stand. Acrylics are still the backbone, and that matters for the downstream, so at this point I’d call it genuinely part of the portfolio, and in any case the results are fairly low—it isn’t even a disposal topic beyond what you mentioned. Now, as you said, and as you’ve seen in Arkema’s history, there’s never any taboo, but for the moment it’s largely a reporting topic, and that’s how we should treat it.
Thanks, Thierry.
Glad to have you with us.
Our following question is from Laurent Favre with BNP. You have the floor.
Yes, good morning, and thanks for taking the questions. My first question, I guess, is on HPP, where we had stable Q2, stable Q3, and Q4, I think, a bit of a collapse, sales down 15%. We saw something similar with your peer this morning. I was wondering if you could talk about what you're seeing beyond, I guess, destocking, what you're seeing on competitive pressures and in particular, maybe some kind of commoditization risk. That's question number one. The second one, just to echo the comments from Matthew, I think best practice for us, especially if you're talking about adding transparency, would be to have sort of restatements for the divisions going back to at least 2023. That would be really, I think, helpful for investors and for us. The question related to that restatement is around acrylics, EU, US. I think it looks like you had €13 million of EBITDA in 2025, and I was wondering how you're thinking about this going forward, as it seems that we'll still have capacity additions in the industry in 2026 and maybe 2027. Are you expecting acrylics EU, US to still be around that sort of breakeven EBITDA for '26 before we eventually see a recovery?
What assumptions did you include in the guidance? Thanks.
Alright. On your first question, I genuinely believe that what happened at year-end — and you also brought up our peers in HPP — was really a result of customers destocking. If we dig into it, you can picture the dynamics needed to truly grasp the results, and beyond the fact that FX impact was larger in Q4 — don't forget that — what we observed is that the destock effect was quite significant, and destocking occurred less in Asia, where culturally customers don't hold much inventory, but it did happen in Europe and the US. As a matter of fact, not only did we have destocking worldwide, but the fact that it was more pronounced in Europe and the US, where our customers culturally carry more stock, shifted the geographical mix. Okay? It weighs on how profitability evolved. The geographical mix — especially the low sales in the US — was a bit of a surprise, but it was tied to this destocking. As you can imagine, we spend a lot of time with our customers in this kind of environment. We came to understand that they would be very cautious about stock at the end of the year. This destocking issue isn't just something affecting the chemical industry.
Customers were reducing their inventories, and so were our suppliers. Everyone attempted to close out the year holding stock that—well, I wouldn't call it minimal, but more sensible relative to where demand stood. To me, this isn't about heightened competition or some unusual shift in how things evolved that we'd have observed in Q4. What it really comes down to is destocking happening customer by customer. As you'd expect, we also monitor our market shares quite closely. Q4 being the final quarter of the year, in some years you get a bit of an exaggerated dip in demand, but I wouldn't view this as any kind of new trend whatsoever. That's not how it feels to me. Within HPP, we've devoted substantial effort to new business development and innovation, and I think there's a paradox here. I believe we've performed well on that front, and growth is indeed present. We can set ourselves apart from the competition, and the market isn't easy, but we're not especially worried about the coming few years. Regarding restatements, I'll relay that message to the Investor Relations team. We'll do whatever we can, but the goal certainly isn't to lose you—quite the opposite, it's to support you.
Set your mind at ease about that—we’ll give it our utmost.
We're ready to provide that support.
Yeah. With acrylics, yes, EBITDA, you could make the math. At least, maybe it's complicated for you, but as you could see, you could try to find some new information that you had not before. It helps you also. I can see you have started to work on the acrylic. No, clearly we're surprised by the let's say the depth of the cycle of acrylics. In fact, we have to go back to 2010 and the acquisition of the acrylics from Dow, where the cycle were more or less that one. I don't know if it makes you more comfortable, a year after, it was one of our best product lines. I think everybody has to be modest on anticipating. I think that acrylic in Europe and US was more under pressure than expected clearly in '25. We expect for the time being maybe hopefully a little bit of improvement, but something not far from what we saw in '25.
Thanks.
Happy to have you.
Up next, we have a question from Emmanuel Matot at ODDO BHF. Emmanuel, the floor is yours.
Hi Thierry, hi Marie-José. I have three questions. First, is it reasonable to think H2 could match H1 on EBITDA? Is that the kind of seasonality you’re building into the 2026 guidance? Historically, that would be quite unusual. Second, why do you anticipate those projects contributing less incremental EBITDA to the group in 2026? You’re citing only €50 million versus €60 million last year, which seems cautious. Finally, do you sense that European authorities are now more prepared than before to assist you and the sector in achieving a significant recovery in competitiveness and to shield you better from unfair competition, especially from China? Thank you very much.
Thank you, Emmanuel, for that question. Regarding the first point, we never claimed it would be equal. What we said is that it would be more balanced, since '25, by contrast, was atypical when it comes to seasonality — but we did not state it would be at par between H1 and H2. It's simply that the imbalance in '25 would return closer to normal, I would say. On the project, no — in fact, it may be counterintuitive, but it isn't because you do 60 one year and 50 the next; we're talking about incremental, as additional EBITDA. Okay? It hinges on the momentum of the project. If in '24 you had a project that was started in '25 with a first step that was very high in terms of contribution, the following year that same project can deliver far less, on top of it. Beyond that, you can deliver on a project — I don't know, let me give you an example. You deliver over five years €100 million, you can have 40 the first year, 20 the second year, and then 10, etc. It's not linked. What matters is the cumulative, and it hinges on the phasing of the project.
A few of these got underway 3 years back, while others only kicked off at the close of last year. I'd say there's no connection between them. What matters is that they add up over time. Being careful can only help. The macro will play a role, but my view is that we ought to plan on €50 million. That strikes me as sensible. Beyond the numbers, the bigger point is our confirmation that the project's positioning remains entirely sound strategically and geographically. I see that as good news. It means that, with the world shifting, your question might equally have been whether some of our projects have stopped being relevant now that circumstances have changed. That isn't the situation. We genuinely reaffirm how solid these projects are. Each one carries real meaning, even where development takes longer than we originally expected. On your final question, yes — to begin with, we operate globally; this isn't Arkema protected, it's Arkema's assets in Europe, yet our assets span the world, and in the end we'll be pragmatic. Much as we value our region and our country, our money will go where we think we can stay competitive and grow.
Turning to Europe: yes, the authorities there have grasped the risk facing the industrial assets of a chemical company, and not only within chemicals in Europe. They appear to be more conscious of that risk, more inclined to protect, and to give more thought to competitiveness. On awareness and intent, so to speak, I'd call it positive. On action, as of now, we are seeing nothing, or very little.
Chetan Udeshi from JPMorgan has the next question. Go ahead, please.
Hi. Thanks for taking my question. I’ve got maybe two, maybe three — I’m not sure — but I’ll try. The first one was just that I’m looking at your Advanced Materials Q4 numbers, and you’re saying you had destocking, but then your revenue in Q4 is actually above Q3, and your EBITDA has been — it seems revenue is up €10 million versus Q3, EBITDA is down €40 million versus Q3 — I’m just curious what happened there. Maybe just to challenge your comment that Arkema is doing very well in Specialties. It doesn’t seem, when I look at your numbers in Adhesives or Advanced Materials, that that’s really coming through in terms of numbers. The EBITDA in both these divisions are down quite dramatically year on year. Just curious why you think we should think Arkema is doing well and there is not a competitive pressure that is coming through in the business. The last question I had was just in Q1 — sorry, Q1 guidance — historically, if I go like many years back, your typically Q1 will be up 20% to 30% versus Q4. In the last two years, we’ve had a more modest improvement of 1% to 5%. What should we think in terms of the magnitude of that seasonal rebound that we should have in mind for Q1?
Thanks.
Chetan, let me try to get at what you're asking, because you're putting Q4 next to Q2 — is that on Advanced Materials, or no, I believe on Advanced Materials this is the reply to Laurent, and it's the destock. As I mentioned, the destock — which didn't happen in Q3 — occurred mainly in Europe and the US. Destocking in the US has been strong, and that's the region where, in terms of added value, we come in higher than Asia. The geographical mix is going against us. That's it. You have all the figures there. In the end, though, it really comes down to the destock and the geographic mix. We have some high-value applications in Europe and the US that destocked completely. Sometimes in December you simply get no order, because your customers are just optimizing their stock. That's what happened. From what I see among other peers that I know — some peers you particularly track — you can observe that destocking happened across the board at many peers. I'd say no, I stand by what we've said. Then your second question, Béatrice?
That comes down to the seasonal pattern between Q1 —
No, there was a different one.
We mentioned that Specialties is performing well for us,
However, Chetan.
It appears to indicate that Adhesives and Materials didn't perform so well.
I suppose I'm not entirely sure what you're asking, but here's what we're saying: I'm confident you're pointing to what I told Matthew about transparency and the reason we changed segmentation. What we stated very plainly is that Specialty Material's EBITDA fell 5% across the year, and in a macroeconomic environment we regard as among the worst in 30 years, that result demonstrates the quality of this portfolio — that's it. Beyond that, you're entitled to your own view, as always, but we believe that a minus 5% EBITDA on 85% of the portfolio, under genuinely more than tough conditions, is a performance that deserves recognition and should be highlighted. That's what we're doing, and we think it was worth doing. On Q1 guidance, we won't get into precise figures. All we can say is that Q1 will come in above Q4. Seasonality is there. The macro picture is comparable. Destocking certainly ought to be lighter, and the typical seasonality is more favorable in Q1. We accept that in recent years it has been somewhat less elevated relative to Q4 than used to be the case.
You’ve got some reference points you can use, but I think this is a qualitative element, and it certainly won’t be the kind of seasonality you could find a few years ago. It’s more typical of the more recent years, but Q1 will be above Q4 — no surprise there. The macro should be quite comparable, but the destocking will be less also. Okay?
Thanks.
Also, keep in mind the €25 million currency effect we talked about.
Understood. Thanks.
Our following question is from James Hooper at Bernstein. Please proceed.
Morning, and thanks a lot for taking my question. Could we dig a bit further into the outlook, please? More specifically, on a division-by-division basis, if that's doable. The other thing I'd like to get my head around is obviously your guidance for the €50 million cumulative effect from the projects. Does that involve any cannibalization impact on some of the existing revenues? I'm just trying to bridge to how this works, and also the kind of impact of the Specialty groups versus refrigerants. Thanks very much.
On the outlook, I believe you have our press release and what we’re able to say at this point regarding guidance. We have not provided—and I believe we never have provided—any guidance by division. Our guidance is for the entire company. That said, on the macro, and this was our view in 20 in ’25, particularly if you look at the new segmentation, I’d say the macro is similar across each business. Their geographic footprint is fairly comparable. The end markets differ somewhat, but all of them are diversified by end market. I wouldn’t draw a major distinction by division. Then there was Laurent’s question on Primary Materials, with the weight of acrylics, etc., where we believe it will remain, at least during the first part of the year, at a low level. Beyond that, I think the macro should be similar. Now, in Advanced Materials, you will gain more from the project than the other division. You could see that if you take the list of projects, it is more in Advanced Materials and in Adhesives—but certainly Advanced Materials—than the other division. Construction in Europe, as we mentioned, I think should provide more support to Adhesives and the Coating.
I'm sure you also took into account old-generation refrigerant when looking at Primary Materials. There are some nuances depending on the division you mean. Overall it's a similar picture, though with nuances you're familiar with if you look at our slide, since it shows where the projects sit, and it includes the discussion on construction, the discussion on old-generation refrigerant, and the one on acrylics. On the project, the 50 million, I'm not sure what you mean by cannibalization, but no cannibalization exists. That means at minimum it doesn't take business from another product line. If that's your question — would a new product line replace another one — no, that isn't the case, except with the refrigerant, but refrigerant is one project, and actually it isn't ours. When it comes to the new refrigerant business, the end market differs, so it isn't cannibalization, but we all know old generation disappeared and new generation is arriving. As for everything else, no, I don't see any cannibalization arising from the projects.
Thanks a lot. Could I also squeeze in one quick follow-up regarding the cash outlook, since I don't believe you've provided formal guidance on cash?
Regarding the cash outlook, as we mentioned, assuming comparable macro conditions, cash performance ought to be fairly similar, provided you factor in that working capital stays flat. In fact, for 2025, when it comes to the contribution from the working capital variance—if we assume the macro picture remains comparable—then no change in working capital is expected in '26.
I appreciate that. It's useful. Many thanks.
Mr. Le Hénaff, at this point we don't have any further questions on the list. I'll hand it back to you for any closing remarks you'd like to make.
Yes. Thank you so much for listening. I believe the year ahead will be quite interesting, just as the last one was. The team, I think, is truly concentrated on the two time horizons. As you're aware and as you've been able to see, the cash and fixed-cost efforts — which matter a great deal — will be carried on with a lot of commitment, and we remain confident about our major projects. That's a very important part. Developing them in the current macro takes longer than we expected, but they will really be a very material contributor over the coming years. Beyond that, we confirm that we hold genuinely strong positioning across most of our business lines, and even if the macro stays rather weak for the time being, we believe our leadership position is truly a support in this kind of environment. I look forward to meeting you on different occasions, and have a good day. Thank you.
That wraps up today’s conference call, everyone. Arkema appreciates your taking part. You’re welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Arkema S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Arkema S.A. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.